AlzProtect continues the clinical development of its drug candidate AZP2006 that is currently in Phase 1.
The European Medicines Agency has granted orphan drug designation to AZP2006 for the treatment of Progressive Supranuclear Palsy.
AlzProtect seeks to raise funds to finance the next clinical trials with AZP2006.
Partnerships or collaborations with public or private partners
We have no job vacancies for now. Spontaneous applications may be sent to email@example.com
For information, please send an email to firstname.lastname@example.org